Compare Salesforce Inc (CRM) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs DexCom, Inc. — how do they compare? Salesforce Inc trades at $168.09 (market cap $137.23B), while DexCom, Inc. trades at $74.44 (market cap $28.60B). The key difference: Salesforce Inc is far larger — about 4.8× DexCom, Inc.'s market cap, and Salesforce Inc pays a 1.05% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| CRM | DXCM | |
|---|---|---|
Market Cap | $137.23B | $28.60B |
Sector | Technology | Health |
52-Week High | $270.25 | $89.53 |
52-Week Low | $150.12 | $54.84 |
Enterprise Value | $167.28B | $27.57B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $168.75, down 1.44% on the day amid a broader tech sell-off. The stock exhibits a neutral technical signal with support near $165 and resistance at $171. Fundamentally, the company shows strong profitability with a 77.64% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights AI-driven growth potential but also reflects market concerns over software stock volatility.
The outlook remains positive given robust earnings beats, high analyst buy ratings (76.84%), and a consensus price target of $235.90, implying significant upside. Key risks include competitive pressures in AI, macroeconomic sensitivity, and the stock's high valuation multiples. Revenue growth and AI monetization are critical catalysts for future performance.
DXCM trades at $76.35, up 1.85% today, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 17.93% net income margin and consistent earnings beats. Recent regulatory approvals for G7 15-day CGM in Canada and pediatric clearance for Stelo OTC system highlight growth catalysts. Revenue growth accelerated to $4.66 billion in 2025, up from $4.0 billion in 2024.
DXCM presents a compelling growth story with expanding CGM market access and strong analyst support (80% buy ratings). Key risks include GLP-1 adoption impact on core market and execution of Type 2 non-insulin patient expansion. The stock trades at a premium valuation (P/E 32.76) but offers upside to consensus target of $83.78. Near-term focus on Q2 2026 earnings release July 30.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
